CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
同种异体嵌合抗原受体（CAR）作为多发性骨髓瘤的“现货型”疗法
英文原题：Allogeneic chimeric antigen receptors (CARs) as an "off-the-shelf" therapy in multiple myeloma.
查看英文原题
Allogeneic chimeric antigen receptors (CARs) as an "off-the-shelf" therapy in multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
自体嵌合抗原受体（CAR）-T细胞的成功改变了复发/难治性多发性骨髓瘤（MM）的治疗格局，使CAR-T 细胞有可能前移至一线治疗。然而，该疗法最大的弱点之一是其自体性质，这使得治疗耗时、劳动密集，并依赖于患者T细胞的适应性。异体CAR的开发对于克服这些挑战并为患者提供 readily available 的现成替代方案至关重要。本综述将探讨异体CAR研究在MM中的当前格局和未来前景，审视临床前研究和正在进行的临床试验。更具体地说，它将聚焦于各种CAR细胞候选物的优缺点，包括CAR-T、CAR-NK和CAR-iNKT细胞，以及其他更新颖的候选物。
展开英文摘要原文
The success of autologous chimeric antigen receptor (CAR)-T cells has changed the treatment landscape in relapsed and refractory multiple myeloma (MM) resulting in potential movement of CAR-T cells to the frontline treatment setting.
However, one of the greatest weaknesses of this therapy is its autologous nature, which makes it time-consuming, labor intensive, and dependent on the patient's T cell fitness. The development of allogeneic CARs is critical to overcome these challenges and provide patients with an off-the-shelf alternative that is readily available.
This review will investigate the current landscape and future perspectives of allogeneic CAR research in MM, exploring both pre-clinical research and active clinical trials. More specifically, it will focus on the advantages and disadvantages of various CAR cellular candidates including CAR-T, CAR-NK, and CAR-iNKT cells, among other more novel candidates.
论文信息
- 作者
- Carlson S、Lin TL、Larson SM
- 单位
- Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, CA, USA.United States
- 文献类型
- 综述
- 期刊
- Immunotherapy2025 Feb
- 原文标识
- PubMed 39961649 · DOI 10.1080/1750743X.2025.2461987